A phase 3, open-label trial to evaluate the safety, tolerability, and immunogenicity of a 13vPnC when administered to healthy Japanese adults aged greater than or equal to 65 years and 50 to 64 years in Japan who have not received a previous dose of 23-valent pneumococcal polysaccharide vaccine

Trial Profile

A phase 3, open-label trial to evaluate the safety, tolerability, and immunogenicity of a 13vPnC when administered to healthy Japanese adults aged greater than or equal to 65 years and 50 to 64 years in Japan who have not received a previous dose of 23-valent pneumococcal polysaccharide vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2011

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Wyeth
  • Most Recent Events

    • 12 Aug 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2008 Actual number of patients is 270 as reported by ClinicalTrials.gov.
    • 29 Apr 2008 Status changed from recruiting to in prgoress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top